The aim of this study is to compare the time course of cytokines (markers for inflammation) in the following 3 groups: RSV-positive, ventilated patients; RSV-positive, non-ventilated patients and RSV-negative, ventilated patients. The main…
ID
Source
Brief title
Condition
- Respiratory tract infections
Synonym
Research involving
Sponsors and support
Intervention
Outcome measures
Primary outcome
An undiluted nasopharyngeal aspirate (NPA) will be taken within 1 hour before
intubation followed by an endotracheal aspirate (ETA) at 6, 24 and 48 hours
after intubation. In non-intubated patients a NPA will be taken at 0, 6, 24 and
48 hours after the first NPA. Cytokine concentrations in NPA /ETA will be
determined; IL-1, IL-6, TNF-*, IL-10 and IL-8 will be measured using the
Luminex fluorescent-bead-based technology. Of the ventilated patients, 2 ml
blood will be collected every 48 hours for immunological studies.
Secondary outcome
Not applicable
Background summary
Respiratory Syncytial Virus (RSV) lower respiratory tract infection (LRTI) is
the most frequent cause of Pediatric Intensive Care Unit (PICU) admission for
mechanical ventilatory support in infants during the winter season. Life-saving
mechanical ventilation (MV) however may induce or aggravate pulmonary
inflammation and lung injury. When pulmonary inflammation is already present
when MV is applied, this inflammation is probably enhanced. Therefore, it is
reasonable to assume that MV will profoundly modulate RSV induced inflammation.
Currently, the role of ventilation-induced lung injury (VILI) is studied by the
applicants in a mouse model. The aim of the proposed study is to translate the
same hypothesis to humans: mechanical ventilation aggravates RSV-induced airway
inflammation.
Study objective
The aim of this study is to compare the time course of cytokines (markers for
inflammation) in the following 3 groups: RSV-positive, ventilated patients;
RSV-positive, non-ventilated patients and RSV-negative, ventilated patients.
The main hypothesis is that MV aggravates RSV-induced airway inflammation as
determined by repeated measurement of local cytokine concentrations.
Study design
The pilot study will be an observational multi-center, prospective, case
control study.
Study burden and risks
From each patient a maximum of 4 samples [aspirates] will be obtained.
Burden:
* Nasopharyngeal aspiration is a non-invasive technique where mucus is
suctioned from the nose. The burden for the patient is low, consisting of
discomfort during less than 10 seconds. Most children admitted to the hospital
for respiratory illness during the winter season undergo this diagnostic
procedure to determine if they are RSV positive or negative. Also due to
obstruction of the nose by mucus the nose will be suctioned frequently in LRTI
patients. Medical staff is experienced with this technique. No complications
have been described.
* Endotracheal aspiration is a non-invasive technique where mucus is suctioned
from the endotracheal tube. The burden for the patient is low and all children
requiring mechanical ventilation, regardless of the reason for their
respiratory insufficiency, undergo this procedure routinely several times per
day to prevent endotracheal tube obstruction and subsequent ventilator
problems. Endotracheal suctioning is also used for several diagnostic
procedures and poses little risk. No complications have been described.
* Bloodsampling: Every 48 hours 2 ml blood is taken from a central venous,
arterial catheter or during peripheral venous cannulation during anesthesia for
cellular immunological studies. This amount has been considered safe by the
WKZ/UMCU METC in our previous studies in a population with identical inclusion
criteria.
Possible benefit:
There is no clear clinical benefit for the infants participating in this
proposed study.
* Nasopharyngeal aspiration: the sample before intubation is necessary to clear
the upper airways (infants obligatory breathe through the nose). Subsequent NPA
samples have no possible benefit.
* Endotracheal aspiration: preventing tube obstruction and therefore avoiding
ventilator problems.
Postbus 85500, huispostnummer D01.343
3508 GA, Utrecht
NL
Postbus 85500, huispostnummer D01.343
3508 GA, Utrecht
NL
Listed location countries
Age
Inclusion criteria
Index group (n<=25):
* Age < 13 months
* Strong suspicion or proven RSV LRTI (positive PCR or DIFF)
* Respiratory insufficiency requiring mechanical ventilation
Ventilated control group (n<=25):
* Age < 13 months
* Mechanical ventilation for elective surgery (e.g. diagnostic cardiac catheterisation, hernia inguinalis correction)
Non-ventilated control group (n<=25):
* Age < 13 months
* Proven RSV LRTI
* Hospitalisation due to RSV LRTI (e.g. for oxygen suppletion, nasal gastric tube feeding)
Exclusion criteria
* Previous airway morbidity in all groups
* Severe co-morbidity (p.e. congenital heart disease, prematurity <33 weeks) in the index group
* Current signs of airway infection (runny nose) in the ventilated control group
* Cardiac surgery less than 3 months before elective diagnostic cardiac catheterisation or cyanotic cardic disease in the ventilated control group.
Design
Recruitment
metc-ldd@lumc.nl
metc-ldd@lumc.nl
metc-ldd@lumc.nl
metc-ldd@lumc.nl
Followed up by the following (possibly more current) registration
No registrations found.
Other (possibly less up-to-date) registrations in this register
No registrations found.
In other registers
Register | ID |
---|---|
CCMO | NL25193.098.08 |